Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00930683 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
A Phase 1 study of Scleroderma, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 11
- Study locations
NCT00930683: Completed Phase 1 study of Scleroderma, sponsored by MedImmune.
NCT00930683 is a Phase 1 study of Scleroderma that has completed, run by MedImmune. The registered enrollment target is 34 participants, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (92% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00930683, a Phase 1 study of Scleroderma, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 11
- Study locations
Study Summary
To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.
Conditions Studied
Interventions
- DRUG MEDI-546
Study Locations (11)
Texas
- Metroplex Clinical Research Center - Dallas
- Research Site - Houston
Utah
- University of Utah Medical Center - Salt Lake City
- Research Site - Salt Lake City
California
- Research Site - Los Angeles
Massachusetts
- Boston University - Boston
Michigan
- Research Site - Ann Arbor
New Jersey
- Research Site - New Brunswick
New York
- Research Site - Lake Success
Ohio
- Research Site - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
What the finished NCT00930683 record still lists
NCT00930683 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 1 intervention - of which MEDI-546 is the first listed.
NCT00930683 lists 11 locations in 9 states (Texas, Utah, California).
Frequently Asked Questions
What is clinical trial NCT00930683 about?
NCT00930683 is a clinical study titled "A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma". To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.
What is the current status of trial NCT00930683?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2009-09. Estimated completion is 2011-07.
What conditions does trial NCT00930683 study?
This clinical trial studies the following conditions: Scleroderma.
What interventions are being tested in trial NCT00930683?
The interventions under investigation include: MEDI-546 (DRUG).
Who is sponsoring clinical trial NCT00930683?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00930683 being conducted?
This trial has 11 study locations across California, Massachusetts, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00930683's enrollment target sits among peer trials
34 17th of 23 higher than 7 of 23 other Scleroderma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scleroderma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
TENS in Scleroderma
RECRUITING · Phase 1
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
Scleroderma Registry & Repository at the Hospital for Special Surgery
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia